TrialNature communications2025

Randomized phase I trial outcomes show safe and sustainable inhibition of classical and lectin complement pathways by empasiprubart.

Inge Van de Walle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.